Serotoninergic dysfunction in the 47, XYY syndrome.
In six XYY patients suffering from aggressiveness and admitted by order of law into a security setting for acts of violence, the estimation of cerebrospinal fluid amine metabolites before and after a probenecid test revealed a clear decrease in the turnover of central serotonin (5-HT) while that of dopamine (DA) was unchanged. The treatment with the 5-HT precursor, L-5-hydroxytryptophan (L-5-HTP), in five of the XYYs resulted in a clinical status equivalent to that observed when the patients were previously treated by conventional neuroleptics.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000328:Adult; D004298:Dopamine / Q000378:metabolism; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D011339:Probenecid; D012701:Serotonin / Q000378:metabolism*; D012729:Sex Chromosome Aberrations / Q000503:physiopathology*; D014997:XYY Karyotype / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000503:physiopathology*
D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; D006916:5-Hydroxytryptophan; D011339:Probenecid; D004298:Dopamine; D006719:Homovanillic Acid